Skip to main content
Otofarma S.p.A. logo

Otofarma S.p.A. — Investor Relations & Filings

Ticker · OTO ISIN · IT0005663361 LEI · 815600FED560ACA5D783 Euronext Growth Manufacturing
Filings indexed 19 across all filing types
Latest filing 2026-04-22 Regulatory Filings
Country IT Italy
Listing Euronext Growth OTO

About Otofarma S.p.A.

https://www.otofarmaspa.com/

Otofarma S.p.A. is a company active in the audiological field, specializing in the design, manufacture, and distribution of custom-made hearing aids. The company provides personalized hearing solutions engineered for comfort and discretion, addressing various types of hearing needs. Its product range includes in-the-ear models, such as the Endo and CIC series, and behind-the-ear devices like the Retro Micro series. Otofarma also offers a teleaudiology service, which facilitates remote otoscopic and audiometric examinations to ensure the precise fitting and customization of its hearing aids for individual patients.

Recent filings

Filing Released Lang Actions
OTOFARMA: PERFEZIONATO IL CLOSING PER IL NUOVO STABILIMENTO A MILANO
Regulatory Filings Classification · 1% confidence The document is a regulatory press release (“Informazione Regolamentata n. …”) from Otofarma announcing the completion (“perfezionato il closing”) of the asset purchase for a new production facility in Milan. It is not an earnings release, shareholder vote, financing update, or other specific report type (e.g., 10-K, IR, M&A bid, dividend notice, etc.). It is a short corporate announcement distributed via the EMARKET SDIR system that does not fit one of the narrow categories, so it should be classified under the fallback “Regulatory Filings” category (RNS).
2026-04-22 Italian
OTOFARMA: CLOSING COMPLETED FOR THE NEW FACILITY IN MILAN
Regulatory Filings Classification · 1% confidence The document is a Teleborsa-regulated press release announcing the completion of a €1.5 million property acquisition (new Milan facility) by Otofarma. It is not an annual or interim report, not an earnings release, not a financing or capital-raising update, nor a share issuance or M&A takeover of another company. It is a general corporate event announcement under a regulated information system in Italy and does not fit a more specific category. Therefore it falls under the fallback “Regulatory Filings” category.
2026-04-22 English
OTOFARMA: 2026 CORPORATE EVENTS CALENDAR
Regulatory Filings Classification · 1% confidence The document is a press release from Otofarma announcing its '2026 Corporate Events Calendar'. It lists upcoming dates for board meetings and shareholder meetings. This type of announcement, which provides a schedule for future reporting rather than the reports themselves, is classified as a Report Publication Announcement (RPA) under the provided definitions.
2026-01-28 English
OTOFARMA: CALEDARIO EVENTI SOCIETARI 2026
Regulatory Filings Classification · 1% confidence The document is a press release from Otofarma announcing its 'Calendario Eventi Societari 2026' (2026 Corporate Events Calendar). It lists the dates for upcoming board meetings and shareholder meetings regarding financial results. According to the 'Menu vs Meal' rule, this is an announcement regarding the timing of future reports rather than the financial reports themselves. Therefore, it is classified as a Report Publication Announcement (RPA).
2026-01-28 Italian
Otofarma: fa l'ingresso in azienda il nuovo CFO Nicola Mottola
Board/Management Information Classification · 1% confidence The document is a press release announcing the appointment of a new Chief Financial Officer (CFO) at Otofarma. It details the professional background of the new appointee, Nicola Mottola, and discusses the strategic strengthening of the company's management structure. According to the filing definitions, announcements regarding changes in senior management fall under the 'Board/Management Information' (MANG) category.
2026-01-08 Italian
Otofarma: Nicola Mottola the newly appointed CFO
Board/Management Information Classification · 1% confidence The document is a press release announcing the appointment of a new Chief Financial Officer (CFO) at Otofarma. It details the professional background of the new appointee, Nicola Mottola, and discusses the strengthening of the company's management structure. This falls directly under the definition of 'Board/Management Information' (MANG), which covers announcements of changes in senior management.
2026-01-08 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.